Approvals, financings, and platform shifts across six beats, and what each one means for the decision in front of you. Written for founders, investors, and operators who need the read before the market has one.
Get the brief
Free. Takes about five minutes to read.
A single brief covering what moved across all six beats. No daily alerts and no drip sequence.
After your email, you can choose which beats matter most to you. Skip it and you get everything.
No paywall and no cost. Every email has a one-click unsubscribe, and we do not sell your address.
Baxter’s Round Lake facility received an FDA warning letter after inspections in March and April found shortcomings in efforts to prevent antibiotics from contaminating other drug products. The agency said repeated failures at multiple sites show management oversight and control over drug manufacturing is inadequate, raising the stakes beyond a single plant response.
At the MSToronto2026 conference, Roche presented additional data linking fenebrutinib to effects on chronic active lesions, disability progression and brain volume loss. The update matters because physicians and investors increasingly view confirmed disability progression as a key differentiator for the next wave of MS medicines.
AI Proteins designs de novo miniproteins using a computational platform aimed at building molecules for a specified therapeutic task rather than adapting nature-derived biologics. Astellas will handle development, regulatory processing, and commercialization of any resulting assets, keeping the collaboration focused on upstream discovery while reserving downstream value for the larger pharma.
Hibsago is designed to reduce hepatitis B viral messenger RNA so some patients can stop treatment after up to 24 weeks and maintain viral control afterward. The decision gives GSK a first-in-class product, while also providing a commercial and technical validation point for Ionis’ antisense platform.
The Eagle Insights Dashboard aggregates ratings on areas including study start-up and planning, contract language, communication, representative patient populations, and technology. SCRS said the platform will add 2025 and 2026 data by November, allowing organizations to track trends over time.